1430亿！GE医疗公布2025全年业绩

Core Viewpoint - GE Healthcare's 2025 annual report shows revenue and earnings per share exceeding market expectations, with clear guidance for growth and profit recovery in 2026 despite macroeconomic challenges [1][2]. Annual Performance - In 2025, GE Healthcare achieved revenue of $20.6 billion (approximately ¥143 billion), a year-on-year increase of 4.8%, with organic revenue growth of 3.5% [3]. - The growth was supported by three core business segments, indicating a structural foundation rather than reliance on single products or short-term projects [4]. - The order performance is promising, with a backlog providing good visibility for 2026 [5][6]. Fourth Quarter Insights - In Q4 2025, GE Healthcare reported revenue of $5.7 billion, a 7.1% year-on-year increase, with organic growth of 4.8% [8]. - However, profit margins faced short-term pressure due to rising tariff costs and unfavorable product mix changes [9][10]. - The net profit margin was 10.3%, down 320 basis points year-on-year, while adjusted EBIT margin was 16.7%, down 200 basis points [11]. Profitability Analysis - The decline in profit margins is attributed to external factors rather than operational inefficiencies, with management emphasizing that excluding tariff impacts, profit margins were higher than in 2024 [14][15]. - This context supports GE Healthcare's guidance for a 50-80 basis point profit margin recovery in 2026 [16]. Regional and Demand Analysis - Growth in 2025 was primarily driven by the U.S. and EMEA markets, aligning with long-term healthcare system demands for imaging equipment upgrades and advanced diagnostic capabilities [17][18]. - GE Healthcare's diversified revenue streams provide stronger resilience against cyclical fluctuations [18]. Cash Flow and Capital Allocation - GE Healthcare maintained a solid cash flow position, with $4.5 billion in cash and $3.5 billion in available credit lines, allowing for ample space for acquisitions and long-term investments [22]. - The company announced plans to acquire Intelerad for $2.3 billion, enhancing its enterprise imaging capabilities [24]. Product and Innovation Strategy - In 2025, GE Healthcare focused on platform-based innovations rather than merely launching new products, emphasizing long-term value creation in imaging and diagnostics [25]. - The company reported operating cash flow of $2 billion and free cash flow of $1.5 billion, with a cash flow conversion rate of 95% [26]. 2026 Guidance - GE Healthcare's guidance for 2026 indicates a focus on profit recovery and cash flow improvement while maintaining steady revenue growth [30]. - The company aims for organic revenue growth of 3%-4%, adjusted EBIT margin of 15.8%-16.1%, and adjusted EPS of $4.95-$5.15 [31].